格隆汇8月18日丨药明康德(02359.HK)发布公告，2025年8月18日耗资2999.76万元人民币回购30.79万股 A股，回购价格每股96.65-99.12元。 ...

药明康德（603259）(02359)发布公告，于2025年8月18日斥资2999.76万元回购A股股份30.79万股，每股 回购价格为96.65-99.12元。 ...

智通财经APP讯，药明康德(02359)发布公告，于2025年8月18日斥资2999.76万元回购A股股份30.79万 股，每股回购价格为96.65-99.12元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 第 1 頁 共 12 頁 v 1.3.0 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % | RMB | 65.96 | ...

序号代码名称最新价涨跌幅主力净流入主力净占比1300759康龙化成30.942.356867.71万元4.17%2600721 百花医药8.7810.036396.54万元25.72%3300015爱尔眼科13.221.34784.89万元2.6%4301235华康洁净 33.2813.393316.13万元5.67%5600763通策医疗46.182.263071.04万元4.73%6301096百诚医药57.12- 10.621489.28万元1.33%7688238和元生物8.566.87869.84万元3.25%8301333诺思格56.751.29781.52万元 5.13%9002524光正眼科4.58-0.43657.94万元7.93%10688246嘉和美康36.723.15585.47万元3.17% 8月18日，医疗服务行业上涨1.26%，今日主力资金流出14.05亿元，成分股33只上涨，9只下跌。 主力资金净流出居前的分别为药明康德（4.78亿元）、创新医疗（4.1亿元）、凯莱英（1.75亿元）、三 博脑科（1.57亿元）、睿智医药（5473.37万元）。 来源：金融界 ...

作者：金股通 本文源自：金融界 截至8月18日开盘一小时，主力资金流出前20的股票分别为：卧龙电驱（-15.18亿元）、天风证券 （-14.58亿元）、东方财富（-11.00亿元）、衢州发展（-6.03亿元）、中银证券（-5.19亿元）、工业富 联（-4.52亿元）、上海电气（-4.50亿元）、金发科技（-4.13亿元）、指南针（-4.07亿元）、凯美特气 （-4.03亿元）、万通发展（-3.61亿元）、英维克（-3.37亿元）、国盛金控（-3.32亿元）、东山精密 （-3.06亿元）、恒宝股份（-2.95亿元）、药明康德（-2.90亿元）、中国神华（-2.61亿元）、中电鑫龙 （-2.54亿元）、宁波韵升（-2.52亿元）、飞龙股份（-2.42亿元）。 ...

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

Group 1 - The stock price of WuXi AppTec closed at 97.80 yuan on August 15, 2025, down by 0.89% from the previous trading day [1] - The company operates in the medical services industry and is a global leader in pharmaceutical research and development services, covering drug discovery, development, and manufacturing services [1] - For the first half of 2025, WuXi AppTec reported revenue of 20.799 billion yuan and a net profit attributable to shareholders of 8.561 billion yuan [1] Group 2 - On August 15, WuXi AppTec repurchased 290,000 A-shares, with a total payment amount of 27.99 million yuan [1] - On the same day, the net outflow of main funds was 236 million yuan, while the cumulative net inflow of main funds over the past five trading days was 1.119 billion yuan [1]

Group 1 - The core index, the CESHKB, increased by 1.74% to 9852.81 points with a trading volume of 14.774 billion [1] - The CESHKB index has risen by 20.92% in the past month, 69.27% in the past three months, and 116.13% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten weighted stocks in the CESHKB index include: - CanSino Biologics (13.72%) - Innovent Biologics (9.48%) - 3SBio (8.99%) - WuXi Biologics (8.61%) - BeiGene (8.53%) - WuXi AppTec (6.93%) - Kintor Pharmaceutical (4.94%) - Zai Lab (4.28%) - Nuo Therapeutics (4.1%) - Genscript Biotech (3.78%) [1] - The CESHKB index is entirely composed of stocks listed on the Hong Kong Stock Exchange, with 100% allocation [2] - The index's holdings are exclusively in the healthcare sector, with 100% allocation to the pharmaceutical and healthcare industry [2]

药明康德（603259）(02359)发布公告，该公司于2025年8月15日斥资2799.09万元人民币回购28.55万股A 股，每股回购价格为96.71-99.28元人民币。 ...